Company news
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) news
Protagonist Therapeutics, Inc. news releases on 6ix. Latest, Sep 8, 2026: Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Press releases & updates
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
September 8, 2026
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
September 2, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
August 28, 2026
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 5, 2026
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
June 1, 2026
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
May 28, 2026
Protagonist Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
May 5, 2026
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
April 27, 2026
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
April 22, 2026
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 27, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 17, 2026
Protagonist Therapeutics : Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 17, 2026
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
March 1, 2026
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
February 24, 2026
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
January 7, 2026
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 4, 2026
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
December 5, 2025
DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 26, 2025
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 2, 2025
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 26, 2025
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
October 6, 2025
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 17, 2025
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
September 16, 2025
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
September 14, 2025
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
September 10, 2025
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
August 25, 2025
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
August 24, 2025
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 5, 2025
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
July 20, 2025
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
June 29, 2025
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
June 25, 2025
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
May 31, 2025
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
May 20, 2025
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 8, 2025
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 5, 2025
Protagonist Therapeutics : Reports Q1 2025 Financial Results and Provides Corporate Update
May 5, 2025
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 22, 2025
Protagonist Therapeutics Reports Granting of Inducement Award
April 15, 2025
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 17, 2025
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 9, 2025
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 8, 2025
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 2, 2025
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 20, 2025
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 28, 2025